Xuebijing injection alleviates liver injury in patients with hepatocellular carcinoma by inhibiting inflammatory response after transarterial chemoembolization

Purpose: To study the influence of Xuebijing (XBJ) injection on patients with hepatocellular carcinoma (HCC) after transarterial chemoembolization (TACE), and to elucidate underlying mechanism action.
 Methods: Thirty-nine HCC were retrospectively analyzed. They assigned 3 groups: negative group which received no XBJ injection, low-dose given (50 ml), high-dose 100 mL injection. Peripheral blood was separately collected andanalyzed first day admission TACE.
 Results: TACE led liver damage in patients, increased serum activities ALT AST, total bilirubin (tBLB). Moreover, elevated white cells, neutrophil count, C-reactive protein (CRP) expression levels inflammation cytokines. In groups treated injection,there dose-dependent mitigation dysfunction, reduced inflammatory cytokines, when compared group. However, did not affect myelosuppression or regulatory T cells.
 Conclusion: dose-dependently decreases injury by suppressing response. Thus, may exert hepatoprotective effect humans clinical practice.